ArticleOcular oncology and pathology2026
Diagnostic Yield of Vitreous Biopsy and MYD88 Mutation Analysis in Vitreoretinal Lymphoma: A Retrospective Cohort Study.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to characterize the clinical, imaging, diagnostic, and treatment features of vitreoretinal lymphoma (VRL) in a tertiary referral center. Methods: Retrospective review of patients with VRL managed at Inselspital, Bern University Hospital, between February 2022 and February 2026. Demographic, clinical, multimodal imaging, biopsy, MYD88 mutation, treatment, and survival data were analyzed. Results: Seventeen eyes from 9 patients were included (median age 70 years): ten eyes with biopsy-confirmed VRL without concurrent CNS lymphoma, and seven eyes with ocular involvement in the context of confirmed CNS lymphoma, including two eyes where ocular diagnosis relied on clinical and imaging findings alone. Mean symptom-to-diagnosis interval was 41 weeks (range 1-104 weeks). At presentation, vitreous cells were present in 94.1% and anterior chamber cells in 29.4%. Posterior segment findings included inner/outer retinal disruption (47.1%), retinal infiltration (29.4%), intraretinal hyperreflective foci (52.9%), irregularity of the RPE (23.5%), CME (23.5%). All patients underwent vitreous or transretinal biopsy, with 11 biopsies performed overall; 8 (72.7%) were cytology-positive. MYD88 mutations were detected in 80% of tested cases (8/10). All cases were reviewed in a multidisciplinary tumor board. VRL without concurrent CNS involvement was mainly treated with local radiotherapy, whereas cases associated with extraocular involvement predominantly received combined systemic immunochemotherapy and radiotherapy. Mean follow-up was 18 months, with no deaths recorded during follow-up. Conclusion: VRL remains a diagnostic challenge due to heterogeneous and nonspecific presentation often leading to a delayed diagnosis. Multimodal imaging, vitreous biopsy, and MYD88 analysis are essential, with MYD88 providing key support in cytology-negative cases. Multidisciplinary management optimizes outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.